Back to top
more

bluebird bio (BLUE)

(Delayed Data from NSDQ)

$1.03 USD

1.03
1,852,538

-0.02 (-1.90%)

Updated May 17, 2024 04:00 PM ET

After-Market: $1.04 +0.01 (0.97%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BLUE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

2 items in cart

View Cart/Checkout

bluebird bio, Inc. [BLUE]

Reports for Purchase

Showing records 461 - 480 ( 530 total )

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 461

03/23/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 462

03/16/2015

Industry Report

Pages: 2

Healthcare - Biotechnology: Key Takeaways From the 27th Annual Conference

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 463

02/26/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 464

02/26/2015

Company Report

Pages: 5

4Q14 EPS, Awaiting SCD Readout, Reiterate Outperform

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 465

02/26/2015

Company Report

Pages: 9

All Eyes on SCD Data and Beta- Thalassemia Regulatory Strategy

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 466

02/23/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 467

02/23/2015

Company Report

Pages: 5

Annuity-Based Payment Structures, An Idea Whose Time Has Come

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 468

02/17/2015

Industry Report

Pages: 3

Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 469

02/03/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 470

02/02/2015

Industry Report

Pages: 5

Canadian Healthcare - Biotechnology Weekly Update

Provider: Clarus Securities

Analyst: NOVAK D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 471

02/02/2015

Company Report

Pages: 5

Regulators Warming Up To Gene Therapy With A BTD For LentiGlobin

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 472

01/30/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 473

01/30/2015

Company Report

Pages: 5

Gene Therapy/Gene Editing Going Mainstream, Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 474

01/21/2015

Company Report

Pages: 5

Raising Estimated LentiGlobin Price, Proof-of-Concept in Sickle Cell Should Drive to New Heights.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 475

01/16/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 476

01/15/2015

Company Report

Pages: 5

SCD, CAR T, And B-Thal Regulatory Strategy Are 2015 Focus Items

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 477

01/06/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 478

01/06/2015

Company Report

Pages: 9

Anticipated Foray into CAR-T, A Major Value Driver, Adding to Focus List.

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 479

12/29/2014

Company Report

Pages: 8

A potential Cure for SCD May Not be Far Fetched, Target to $120

Provider: Roth Capital Partners, Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: bluebird bio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 480

12/29/2014

Industry Report

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party